Takeda set to move from Deerfield Illinois, 1000 jobs affected
pharmafile | September 12, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Jobs, Shire, Takeda, deerfield, illinois
Japanese multinational Takeda is set to shut down its US headquarters in Deerfield, Illinois following the final stages of its Shire Plc acquisition. The company is set to move operations to the greater Boston area, a move that will affect an estimated 1000 workers.
The Deerfield site employs around one fifth of Takeda’s 5000 US employees. Thus although a proportion of those workers affected will be provided with job offers and the chance of relocation, the move is set to cause significant disruption. The company did not provide details as to what percentage of workers will lose their jobs.
The move has come after Takeda was acquired by the Dublin headquartered and London Listed pharma company Shire for £45.3 billion. Meanwhile the acquisition has caused discontent within the Takeda family with company heir Kazu Takeda.
Kazu Takeda said to British newspaper The Times: “We understand that scaling up is necessary, but Takeda management has to think about the traditional corporate culture and the health of the company. Hasty decisions on big deals should be avoided. It will lead to disaster if there are large-scale mergers and acquisitions without careful consideration”
Meanwhile commenting on the move from Deerfield a spokersperson for Takeda’s US operations said:“This move, while difficult, will allow closer collaboration across Takeda to best position our future pipeline for success. It will also simplify our existing Takeda U.S. operations.”
Louis Goss
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
